- Meeting abstract
- Open Access
Rationale for key elements of Sino-American collaboration in clinical research
© Califf; licensee BioMed Central Ltd. 2012
- Published: 17 October 2012
- Congenital Heart Disease
- Translational Research
- Global Population
- Definitive Evidence
- Pompe Disease
When new scientific discoveries are properly evaluated within the translational research continuum and definitive evidence is generated regarding the balance of benefits and risks associated with therapeutic interventions, dramatic health improvements are seen both for individuals and populations. Until recently, however, technological limitations dictated that definitive evidence could be generated for only a fraction of interventions under development, because clinical investigation was limited by geography and access to expertise. Today, less than 15% of major medical decisions are informed by high-quality evidence . Furthermore, increasing knowledge about the roles played by genetics and practice environments demonstrates that we must develop multinational studies to generate evidence relevant to particular biological and cultural contexts . It is now time to begin to plan for a global learning health system.
Modern informatics and information technology have enabled the sharing of research data without regard to geographic boundaries. These new capabilities expand the concept of human biomedical research from an activity conducted in a limited number of specialized centers to a global activity accessible to all patient populations and qualified practitioners . With appropriate informatics support, shared protocols, and facilitative cultural elements, common diseases can be studied on a larger scale and clinical trials in rare diseases will be able to accrue adequate sample sizes, enabling valid inferences to be drawn. In essence, the limits on knowledge generation will henceforth be determined by two key factors: (1) the number of qualified individuals in the clinical and translational research workforce and (2) the degree to which regulatory and funding sources encourage broad-scale collaboration.
Examples of therapeutic areas where progress could be accelerated include diabetes (which affects global populations in large numbers), congenital heart disease (which affects 1% of all global populations) and Pompe disease (a rare disease with a new effective therapy). In each case, collaborative studies between China and the United States—two of the world’s largest funders of biomedical research—could provide the example to stimulate similar activity on a global scale.
Key programs for clinical & translational research
Clinical research training
Epidemiology and global health
Health sector management
- Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC: Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009, 301: 831-841. 10.1001/jama.2009.205. Erratum in: JAMA 2009, 301:1544View ArticlePubMedGoogle Scholar
- Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A: Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA. 2012, 307: 1838-1847. 10.1001/jama.2012.3424.View ArticlePubMedGoogle Scholar
- Dzau VJ, Ackerly DC, Sutton-Wallace P, Merson MH, Williams RS, Krishnan KR, Taber RC, Califf RM: The role of academic health science systems in the transformation of medicine. Lancet. 2010, 375: 949-953. 10.1016/S0140-6736(09)61082-5.View ArticlePubMedGoogle Scholar
- CMS Innovation: Health Care Innovation Awards: Project Profiles – Duke University. [http://innovation.cms.gov/initiatives/innovation-awards/project-profiles.html]
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.